1224 STEMI pts, no reperfusion, < 24 hours from onset

Slides:



Advertisements
Similar presentations
STREAM 1Y AHA 2013 P Sinnaeve STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION.
Advertisements

TIMI 11BESSENCE Enoxaparin for UA/NQMI: TIMI 11B-ESSENCE Meta-Analysis Antman EM et al, Circulation 1999 Oct 12;100(15):
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ACS and Thrombosis in the Emergency Setting
TIMI 11A A Multicenter Trial of the Safety and Tolerability of Two Doses of Enoxaparin in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction.
1 Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction ExTRACT- TIMI 25 ACC 2006 Atlanta, GA Disclosure Statement: Dr. Antman received.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT 3 randomised.
1 ExTRACT-TIMI 25 : New Data Elliott M. Antman, MD This presentation reflects the views of the presenter and does not necessarily reflect the views of.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
Www. Clinical trial results.org Unfractionated heparin 60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50.
No improvement in 30-day mortality with high-dose Glucose-Insulin-Potassium (GIK) infusion CREATE-ECLA - GIK Trial Presented at: American Heart Association.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: The thrombolysis in myocardial infarction risk score.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
AHA 2011 Late Breaking Trials Synthesis and Critical Review.
Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.
Impact of Low-molecular-weight Heparin (Reviparin) on Mortality, Reinfarction, and Stroke in Patients with Acute MI CREATE-ECLA - Reviparin Presented at:
(p for noninferiority = 0.01)
Heparin Should be the First-line Therapy for Patients with ACS/AMI
Clinical Trial Commentary
The American College of Cardiology Presented by Dr. Adnan Kastrati
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
FINESSE: Study Design Acute ST Elevation MI (or New LBBB) within 6h pain onset Presenting at Hub or Spoke with estimated time to Cath between 1 and 4 hours.
PRISM-PLUS: Demographics of Patients With Diabetes
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Ischaemic Heart Disease Acute Coronary Syndrome
Neal Kleiman Director Cardiac Catheterization Laboratory
Seeking the Optimal Upstream Therapy for Patients with ACS: Fondaparinux- Low Bleeding Rate and Low Cost Sanjit S. Jolly MD, Interventional Cardiologist,
Study Design AMI <12 hours, any age, cardiogenic shock excluded
Valsartan in Acute Myocardial Infarction Trial Investigators
The DANAMI-2 Trial Danish Trial in Acute Myocardial Infarction-2
by Thomas Monks, Martin Pitt, Ken Stein, and Martin James
End point Patients >75 y with renal insufficiency
Section E: Clinical trial update: Heparins
The following slides highlight a discussion and analysis of presentations in the Late-Breaking Clinical Trials session from the 55th Annual Scientific.
The following slides highlight a report on a presentation at a symposium and the late-breaking trials session at the American College of Cardiology 53rd.
European Heart Association Journal 2007 April
European Society of Cardiology 2003
SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)
Modified Rankin score 0-2
Section D: Clinical trial update: GP IIb/IIIa inhibition
ARNO TRIAL (Antithrombotic Regimens aNd Outcome)
Randomized Comparison in the Setting of Acute MI
American Heart Association Presented by Dr. Julinda Mehilli
American College of Cardiology Presented by Dr. Michel R. Le May
UFH b 60 U/kg inf 12 U/kg/h >36 h
Erasmus MC, Thoraxcenter
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
(p for noninferiority < 0.001)
ARISE Trial Aggressive Reduction of Inflammation Stops Events
47% 50% 21% Event Rate 35 p= # Pts 20 Death 15
Efficacy and Safety of Enoxaparin vs UFH in ST-elevation MI: A Meta-Analysis of 27,000 Patients Sabina A Murphy C Michael Gibson, David A Morrow, Carolyn.
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Is Bivalirudin Monotherapy Sufficient for Diabetic Patients
European Heart Journal Advance Access
Baseline Characteristics by hs-CRP
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

1224 STEMI pts, no reperfusion, < 24 hours from onset Treatment with Enoxaparin and Tirofiban in acute MI (TETAMI) M.Cohen et al, Beth Israel Hospital, NJ 1224 STEMI pts, no reperfusion, < 24 hours from onset 4 treatment groups Enox 30 mg iv plus 1 mg/Kg sc bd alone Enox 30 mg iv plus 1 mg/Kg sc bd with Aggrastat 100 ug/Kg IV UFH 70 U/Kg plus 15 U/Kg per hour infusion UFH 70 U/Kg plus 15 U/Kg inf. with Aggrastat 100 ug/Kg IV Subgroup analysis showed protective Tirofiban trend in: Pts treated within 12 hours LV dysfunction Study underpowerd for mortality

Outcomes in TETAMI End points (all 30 days) Enoxaparin AHA 2002 review Outcomes in TETAMI End points (all 30 days) Enoxaparin Enoxaparin + tirofiban UFH UFH + tirofiban Randomized patients n=229 n=305 n=306 n=314 Death/ recurrent MI/ recurrent angina 15.4% 16.1% 17.3% 17.2% recurrent MI 8.7% 8.5% 9.2% 8.0% Treated patients n=297 n=303 n=310 Major hemorrhage 1.0% 2.0% 1.6% Hemorrh. stroke 0.0% 0.3% Cohen M. American Heart Association Scientific Sessions 2002.